STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCDA
  4. [Form 4] BioCardia, Inc. Insider Trading Activity

BioCardia (BCDA) CEO Peter Altman makes open-market stock purchase

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of common stock. He bought 5,100 shares at a weighted average price of $1.02 per share. Following this transaction, he directly owns 285,866 shares of BioCardia common stock.

Positive

  • None.

Negative

  • None.
Insider Altman Peter
Role President and CEO
Bought 5,100 shs ($5K)
Type Security Shares Price Value
Purchase Common Stock 5,100 $1.02 $5K
Holdings After Transaction: Common Stock — 285,866 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares purchased 5,100 shares Open-market purchase on May 15, 2026
Weighted average price $1.02 per share Average across multiple trades in the transaction
Post-transaction holdings 285,866 shares Direct ownership after reported purchase
Price range of trades $1.01–$1.03 per share Range of individual trade prices in the transaction
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average per share financial
"The price reported above reflects the weighted average per share sales price."
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
direct ownership financial
"total_shares_following_transaction ... ownership_type: "direct""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Altman Peter
(Last)(First)(Middle)
C/O BIOCARDIA, INC.
320 SOQUEL WAY
(Street)
SUNNYVALE CALIFORNIA 94085
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026P5,100(1)A$1.02(1)285,866D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed in multiple trades ranging from $1.01 to $1.03 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
/s/ David McClung, by power of attorney05/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BioCardia (BCDA) report in this Form 4?

BioCardia reported that President and CEO Peter Altman made an open-market purchase of 5,100 shares of common stock. The transaction reflects insider buying activity, which some investors review alongside other company disclosures.

How many BioCardia (BCDA) shares did the CEO purchase and at what price?

Peter Altman purchased 5,100 BioCardia common shares at a weighted average price of $1.02 per share. The trades were executed in multiple lots between $1.01 and $1.03 per share, according to the filing footnote.

What are Peter Altman’s BioCardia (BCDA) holdings after this transaction?

After the reported open-market purchase, Peter Altman directly holds 285,866 shares of BioCardia common stock. This post-transaction figure comes from the Form 4 and represents his direct ownership stake following the May 15, 2026 trade.

Was the BioCardia (BCDA) CEO’s purchase a direct or indirect holding?

The Form 4 shows the 5,100-share purchase as a direct holding by Peter Altman. The ownership code is listed as “D” for direct, and no trust, partnership, or other indirect ownership entity is referenced for this transaction.

How was the purchase price for the BioCardia (BCDA) CEO’s trade calculated?

The filing notes the transaction was executed in multiple trades between $1.01 and $1.03 per share. The reported price of $1.02 per share represents the weighted average price across all those individual trades on that date.